Literature DB >> 26972689

Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients.

M N Ghazanfar1, C Sand1, S F Thomsen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26972689     DOI： 10.1111/bjd.14540

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  4 in total

Review 1.  Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Authors:  Michael D Tharp; Jonathan A Bernstein; Abhishek Kavati; Benjamin Ortiz; Karen MacDonald; Kris Denhaerynck; Ivo Abraham; Christopher S Lee
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

Review 2.  Chronic urticaria: a focus on pathogenesis.

Authors:  Riccardo Asero; Alberto Tedeschi; Angelo Valerio Marzano; Massimo Cugno
Journal:  F1000Res       Date:  2017-07-11

3.  Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.

Authors:  Martin Metz; Gordon Sussman; Rémi Gagnon; Petra Staubach; Tonny Tanus; William H Yang; Jeremy J Lim; Holly J Clarke; Joshua Galanter; Leslie W Chinn; Tom Chu; Anastasia Teterina; Tracy Burgess; D James Haddon; Timothy T Lu; Marcus Maurer
Journal:  Nat Med       Date:  2021-11-08       Impact factor: 53.440

4.  Omalizumab treatment for chronic spontaneous urticaria: data from Turkey.

Authors:  Rabia Oztas Kara; Bahar Sevimli Dikicier; Mahizer Yaldiz; Busra Koku; Nur Cihan Çosansu; Berna Solak
Journal:  Postepy Dermatol Alergol       Date:  2022-09-01       Impact factor: 1.664
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.